Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update

Slide: 9 of 40

Pharmacologic Agents To Prevent Low Bone Density

Pharmacologic agents investigated in this systematic review include: the bisphosphonates, which include alendronate, risedronate, zoledronic acid, and ibandronate; peptide hormones (teriparatide); estrogen, in the form of menopausal hormone therapy (MHT); selective estrogen receptor modulators (raloxifene); and biologic agents: denosumab.

Not all drugs currently approved by the U.S. Food and Drug Administration (FDA) for treating patients with LBD were required to demonstrate reduction in fracture risk (e.g., the peptide hormone calcitonin). Furthermore, approval of a different dose, frequency, or route of administration does not require demonstration of reduced fracture risk.